{"entity":{"id":"nct07259317","kind":"trial","name":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","aka":[],"tldr":"A phase 2 trial of Relacorilant and Gemcitabine in pancreatic ductal adenocarcinoma, run by Corcept Therapeutics, now recruiting.","summary":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 2 interventional study registered as NCT07259317 by Corcept Therapeutics, with 80 participants planned, started 2026-01-27 and due to reach its primary completion in 2027-09. Interventions recorded: Relacorilant, Nab-paclitaxel and Gemcitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07259317","url":"https://clinicaltrials.gov/study/NCT07259317"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["relacorilant","gemcitabine"],"companies":["corcept"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07259317","phase":"2","setting":"A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)","sponsor":"Corcept Therapeutics","enrolled":80,"outcomes":[]},"route":"/trials/nct07259317/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/"}],"company":[{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/"}]}}